Use of first-line (1L) OPDIVO® (nivolumab) in combination with low-dose YERVOY® (ipilimumab) in certain patients with metastatic NSCLC with PD‑L1 expression ≥1%
According to the American Cancer Society, it is estimated that approximately 228,820 new cases of lung cancer were diagnosed in the United States in 2020, that will result in about 135,720 deaths. In the US, non-small cell lung cancer (NSCLC) comprises 80% to 85% of these lung cancer cases.
Recent advances in the treatment of metastatic NSCLC, with the advent of immune-oncology (I-O) products, have led to improvements in clinical outcomes. The emergence of I-O therapies, used alone or in combination with chemotherapy, has enhanced the treatment paradigm in NSCLC.
Companies have been researching new I-O treatments and approaches to first-line (1L) treatment of NSCLC, including combination treatments for NSCLC with no targetable driver mutation. Nivolumab, in combination with ipilimumab, is approved by the US Food and Drug Administration (FDA) for the 1L treatment for adult patients with metastatic NSCLC whose tumors express PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor alterations.